<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Zhao Z</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Immune checkpoint inhibitors (ICIs) have transformed oncological treatment by modulating immune responses against tumors. However, their efficacy is subject to inter-patient variability and is associated with immune-related adverse events (irAEs). The human gut microbiota, a complex microbial ecosystem, is increasingly implicated in modulating responses to ICIs. This bibliometric analysis examines the 100 most-cited articles to elucidate trends and advancements in research concerning the gut microbiota's impact on ICI efficacy.&lt;h4>Methods&lt;/h4>A systematic literature retrieval was conducted within the Web of Science Core Collection (WoSCC), focusing on the 100 most-cited articles. VOSviewer and CiteSpace were utilized for bibliometric analysis, examining collaborative pat</pubmed_abstract><journal>Frontiers in immunology</journal><pagination>1519498</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11779710</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A bibliometric study on the impact of gut microbiota on the efficacy of immune checkpoint inhibitors in cancer patients: analysis of the top 100 cited articles.</pubmed_title><pmcid>PMC11779710</pmcid><pubmed_authors>Jiang Y</pubmed_authors><pubmed_authors>Xu K</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Zhao Z</pubmed_authors><pubmed_authors>Hu B</pubmed_authors></additional><is_claimable>false</is_claimable><name>A bibliometric study on the impact of gut microbiota on the efficacy of immune checkpoint inhibitors in cancer patients: analysis of the top 100 cited articles.</name><description>&lt;h4>Background&lt;/h4>Immune checkpoint inhibitors (ICIs) have transformed oncological treatment by modulating immune responses against tumors. However, their efficacy is subject to inter-patient variability and is associated with immune-related adverse events (irAEs). The human gut microbiota, a complex microbial ecosystem, is increasingly implicated in modulating responses to ICIs. This bibliometric analysis examines the 100 most-cited articles to elucidate trends and advancements in research concerning the gut microbiota's impact on ICI efficacy.&lt;h4>Methods&lt;/h4>A systematic literature retrieval was conducted within the Web of Science Core Collection (WoSCC), focusing on the 100 most-cited articles. VOSviewer and CiteSpace were utilized for bibliometric analysis, examining collaborative pat</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-04-05T09:32:59.849Z</modification><creation>2025-04-05T09:32:59.849Z</creation></dates><accession>S-EPMC11779710</accession><cross_references><pubmed>39885985</pubmed><doi>10.3389/fimmu.2024.1519498</doi></cross_references></HashMap>